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Abstract: Fit testing procedure is required for filtering facepiece respirators (FFRs) to ascertain an 
acceptable fit between the skin and facepiece sealing surface. The present study seeks to compare 
the efficacy of Aloe vera (A. vera) and commercial BitrexTM as challenge agents of qualitative fit 
testing of particulate respirators. An herbal solution consisting of A. vera at seven different concen-
trations was developed. Threshold Screening Tests (TSTs) of A. vera solutions were compared to 
BitrexTM. To do so, solutions were administered randomly on a total of 62 participants. A placebo 
was also tested to ensure the taste response being valid. Statistical analysis was performed using R 
3.2.5.0 software. There were no statistically significant differences between the A. vera (41.7, 58.3, 
75, and 91.7 mg/ml) and BitrexTM threshold tests. Therefore, the minimum concentration of A. vera 
to develop the threshold solution was considered to be 41.7 mg/ml. When commercial products are 
expensive and unavailable, a cost-effective technique would be to replace A. vera solution with a 
commercial product as a challenge agent of qualitative fit testing of respirators.
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Introduction
Efficient respiratory protection is dependent mainly on 
the filters or cartridges efficiency as well as appropriate-
ness for users’ face and work environment1–3). According 
to the Occupational Safety and Health Administration 
(OSHA), it is mandatory to make sure there is an appropri-
ate fit between a respirator’s facepiece and face seal. To 
meet the legal requirements, it is necessary to do fit testing 
for all subjects included in the Respiratory Protection Pro-
gram (RPP) before the respirator selection4). The ability of 
the respirator to interface with the users’ face to protect the 
respiratory system against hazardous contaminants, named 
“Respirator fit”5).
There are mainly two assessment methods of respira-
tor fit testing per OSHA standard (29 CFR 1910.134), to 
provide the expected level of protection for the wearers6): 
Qualitative fit test (QLFT) and Quantitative fit test (QNFT). 
QNFT uses an instrument to measure the fit factor by di-
viding the ambient particle concentration by the concentra-
tion of particles inside the facepiece of the respirator while 
the user performs a series of simulated work exercises4). 
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QNFT has some advantages such as application to vari-
ous classes of Respiratory Protective Equipment (RPE)7), 
documentation of numerical results, and no chance of 
deception8). However, due to high cost, time-consuming, 
skilled operator, unavailability5), annual recalibration, and 
reliance on a sampling adaptor or probed respirator, QLFT 
is widely being used as the preferred method4, 9, 10).
QLFT is a dichotomous test (pass/fail) that depends 
on the wearer’s olfactory or taste response to a challenge 
agent during the same series of exercises as the QNFT. 
Currently, there are three common challenge agents in-
cluding isoamyl acetate; saccharin; and BitrexTM. Isoamyl 
acetate (IAA), a sweet (banana) smelling vapor is used in 
qualitative fit testing of respirators equipped with organic 
vapor cartridges; whereas, saccharin (sweet taste) and Bi-
trexTM (bitter taste) are the challenge agents for fit testing 
of respirators equipped with particulate filters4). Moreover, 
BitrexTM, the trade name of the bitterest substance, dena-
tonium benzoate (Smith Ltd., Montvale, NJ McFarland), 
generally used as an aversive agent in toxic household 
liquids to decrease the risk of accidental poisoning4).
The most substantial concern about the QLFT is its subjec-
tive nature. It is impossible to do fit testing for all subjects 
in events like pandemics11). It should be mentioned that the 
QLFT is simpler to use11, 12), and cheaper to set up and main-
tain12) than QNFT. But some of the challenge agents like Bi-
trexTM lead to allergic (asthmatic) reactions13, 14), dermal and 
respiratory symptoms, anaphylactic reactions (angioedema 
and bronchospasm), and anxiety response or even an inability 
to detect the taste/smell of the agents13).
Remarkably, some qualifications should be considered 
for selecting a qualitative challenge agent as follows: cost-
benefit, availability, safety, suitability for human exposure, 
and ability to use with any type of approved particular 
filter12). Commercial challenge agents would not be cost-
beneficial or available, furthermore, they might be led to 
symptoms and complications in some subjects as men-
tioned above. Consequently, the efficacy of A. vera was 
compared to BitrexTM.
A. vera is a shining or bitter substance, bitter because of 
liquids such as Aloin, Aloe emodin, and related compounds 
in the leaves15–17). It is approved as Generally Recognized 
as Safe (GRAS) in the US by the Food and Drug Agency 
(FDA)16, 18) and World Health Organization (WHO)18, 19). 
It exerts beneficial effects on human health, including: 
anti-inflammatory17, 18, 20–25), antimicrobial18, 22–24, 26), 
antifungal17, 18), antioxidant and antitumor 23, 27), antican-
cer17, 23, 26, 28), and immunomodulatory properties17, 23, 24). It 
seems that A. vera could be the right substitute for BitrexTM 
as a challenge agent. Also, as stated in ISO 16975-39), 
equivalent substances could be used as challenge agents if 
they behave similar and show identical results. Accordingly, 
the aim of this study was to compare the efficacy of A. vera 
against BitrexTM as a qualitative fit test agent.
Subjects and Methods
Study design
We conducted a single-blind, placebo-controlled, and 
interventional study at Shiraz University of Medical Sci-
ences, Iran.
Participants
Sixty-two students (37 females and 25 males), mean age 
23.45 ± 4.66 yr, using a proportional stratified sampling 
method based on their educational level, were recruited 
for the study. The participants were tested in the Industrial 
Safety laboratory of the School of Health.
First of all, the procedures of this study were approved 
by the Research Ethics Committee of Shiraz University of 
Medical Sciences (approval code IR.SUMS.REC.1396.191). 
Second, all participants were provided explanation about 
study procedures. Then, each was given written informed 
consent documentation. The criteria included an absence of 
the following: (1) allergy to any substance; (2) cold symp-
toms; (3) nasal congestion; (4) cardiovascular or respiratory 
diseases (asthma, shortness of breath, dyspnea);29) rhino-
plasty surgery, or (6) other factors interfering with the sense 
of taste. If any participant developed a cold, the test session 
was postponed until his/her recovery.
Study procedure
All participants refrained from chewing gum, eating, 
and drinking (except for plain water) for 15 min prior to 
the test to ensure they could taste the threshold check solu-
tion (a diluted version of the fit test solution). Meanwhile, 
the placebo solution (distilled water) was tested among 
the solutions randomly to be sure the participants could 
distinguish it. To obtain reliable results, the test assessor 
reminded participants to drink only plain water. A 5-min 
break also allowed participants to clear their palates be-
tween test solutions. These adopted complementary tests 
were illustrated further:
1) To make certain the threshold check solutions hadn’t 
been contaminated, the microbial communications of the 
solutions were assessed. To do so, we utilized the Blood 
Agar for bacteria30) and Sabouraud Dextrose Agar31) 
(Merck Co., Germany) for fungus.
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2) The taste of the solutions was evaluated continuously.
3) The optical molecular spectra of the solutions was 
observed regularly using Agilent Cary 60 spectrophotometer 
(Agilent Technologies, Santa Clara, CA, USA) at 25°C in the 
wavelength range of 200–800 nm to follow up the stability 
of the solutions regarding color, clarity and not construction 
of unstable colloids during the ten months which were pre-
sented in the Supplementary Figs. 1–8 (See online version).
4) The pH of the solutions was measured using a Me-
trohm pH meter model 827 (Metrohm, Herisau, Switzer-
land), according to manufacturer’s instructions (Table 1).
Threshold check solution preparation
Nine different threshold check solutions, including A. 
vera (7 concentrations), a BitrexTM, and a placebo, were 
made. We found that limited amounts of A. vera could not 
significantly affect the taste of the solutions; therefore, 
they were considered for the range of applied concentra-
tions of the A. vera threshold check solutions. The thresh-
old check solutions were poured into identical bottles and 
labeled with unique codes by the administrator. Those 
solutions were randomly allocated to the participants 
based on the Latin Square Design (LSD)12). Accordingly, 
all possible permutation of solutions was 9 factorial (9!). 
Also, all participants were blinded to the ingredient and 
concentration of each solution.
BitrexTM threshold check solution
Moldex® Bitrex® Fit Test Kit Part number 0102 (Moldex 
Co., Culver, CA, USA) contained 0.0135% denatonium 
benzoate, 94.9865%  water, and 5% sodium chloride32).
Aloe vera threshold check solution
We chose the A. vera as equivalent to BitrexTM. A. vera 
solutions were prepared by adding 1.28, 2.26, 3.15, 5, 7, 
9, and 11 gr of A. vera powder to 120 ml of distilled water. 
The above mixtures were boiled at 100°C for 10 min. 
After the solutions had been cooled, they were passed 
through a stainless sieve (US Standard Sieve Mesh No. 200 
(0.075 mm), Pars Sieve, Iran; ASTM E:11). Indeed, the final 
concentrations of the threshold check solutions 10.7, 18.8, 
26.2, 41.7,  58.3, 75, and 91.7 mg/ml, respectively.
Threshold Screening Tests
Threshold Screening Tests (TSTs) were performed 
per OSHA respiratory protection standard, regulation 
29 CFR 1910.1344). The TSTs were aimed to ensure the 
participants’ taste response being valid. Some accessories 
are required to do the TSTs, for instance, hood, nebulizer, 
and paper towel. The poly-coated test hood is approxi-
mately 12 inches (30.5 cm) in diameter by 14 inches 
(35.6 cm) and was placed over a participant’s head and 
positioned forward about 6 inches (15.25 cm) between 
the participant’s face and hood window. The 0.75 inch 
(1.9 cm) hole in front of the participant’s nose and mouth 
area accommodated the nebulizer nozzle and dispersed the 
aerosol with a 2.5 µm mass median aerodynamic diameter 
(MMAD) around the participant’s mouth9) (Fig. 1). More-
over, the nebulizers were periodically checked for aerosol 
generation while squeezing the bulbs. To do so, they were 
held against a dark background to ensure the visible aero-
sol appears. The nebulizers were disassembled based on 
the manufacturer’s manual and rinsed at regular intervals 
to prevent clogging. The hood was wiped frequently with 
a paper towel to clean any deposited solution.
 Prior to starting the intervention, firstly, the participants 
were trained to position the hood over the head without 
donning a respirator, breathing only through their mouths 










Mean ± SD Mean ± SD
Placebo -- - 44 (71) 18 (29)* 15.68 ± 8.04 22.08 ± 11.49
BitrexTM 0. 135 6.91 60 (96.8) 2 (3.2) 5.32 ± 4.18 7.96 ± 4.96
A. vera
10.7 7.50 52 (83.9) 10 (16.1) 7.54 ± 6.32 11.02 ± 7.58
18.8 7.11 43 (69.4) 19 (30.6) 7.65 ± 5.83 10.84 ± 6.8
26.2 7.02 43 (69.4) 19 (30.6) 8.81 ± 7.22 13.58 ± 11.33
41.7 6.70 53 (85.5) 9 (14.5) 7.04 ± 6.016 9.75 ± 6.97
58.3 6.43 53 (85.5) 9 (14.5) 6.87 ± 4.87 9.43 ± 6.01
75.0 6.25 57 (91.9) 5 (8.07) 6.23 ± 5.68 9.12 ± 7.43
91.7 6.14 53 (85.5) 9 (14.51) 4.81 ± 3.07 7.27 ± 3.54
*18 (29%) of the participants reported the placebo as a sweet, salty, or bitter taste.
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slightly open with tongue extended and to report as soon as 
they could detect the taste (not smell) of the challenge agent, 
however, we didn’t notify the participants about the taste 
of the solutions (sweet, bitter, etc.). Secondly, the challenge 
agent was injected in the hood via inserting ten squeezes of 
the nebulizer bulb into the hole in front of the hood. This 
requires the bulb to fully collapse and expand during each 
squeeze cycle. Thirdly, the participants were asked if they 
could detect the taste of the solution. We applied up to a 
total of 30 sprays if required. Also, the taste threshold was 
recorded as ten, twenty, or thirty regardless of the numbers 
of actual performed squeezes (10, 20 or 30 sprays). In other 
words, if the participants could taste between 1–10, 11–20, 
or 21–30 sprays, their threshold levels were classified into 
one of the three classes of High (1), Medium (2), or Low 
(3), respectively. If the participants couldn’t detect the taste 
of the solution after 30 sprays, they were not sensitive to it 
and their threshold test was assigned as a failure; otherwise, 
a pass. The video of Moldex threshold screening procedure 
was played for the participants33).
Lastly, we recorded the study data such as threshold solu-
tion code, the concentration of test solutions (mg/ml), number 
of sprays, time required to elicit a taste response correctly (s), 
threshold level (1, 2 or 3), and test result (pass/fail).
Statistical analysis
The input variables were as follows: type and concen-
tration of the solutions, age, and gender. The outcome 
variables included the results of TSTs (pass/fail). We took 
repeated measures on the participants; thus, the observa-
tions were correlated and the Mixed Effect Logistic 
Regression (MELR) model including random effects was 
proposed34). Noticeably, the model was adjusted for age 
and gender. We calculated the Kappa statistic (k), Brier 
score as the mean square error of taste detection34), and ac-
curacy35) to compare the results of the TSTs. Meanwhile, 
a Receiver Operating Characteristic (ROC) curve analysis 
was obtained to evaluate the detectability of all thresh-
old solutions against placebo (as a reference solution). 
The Area under the ROC Curve (AUC) was calculated 
to determine the overall performance of all threshold 
check solutions against the placebo35). Additionally, A. 
vera threshold solutions (bitter taste)  were compared to 
BitrexTM (as a reference solution). A p-value of 0.05 was 
considered significant. All data analyses were performed 
using R 3.2.5.0 software.
Results
Table 1 shows the TSTs descriptive statistics results.
As shown, the majority of the participants could taste 
BitrexTM and A. vera (75 mg/ml) solutions (96.8% and 
91.9%, respectively). As expected, all solutions (except for 
placebo) were tasted within close margin, in terms of the 
number of sprays and detection time(s).
The results of all threshold solutions tests against 
placebo are shown in Table 2. There were significant dif-
ferences between the BitrexTM and A. vera solutions (41.7, 
58.3, 75, and 91.7 mg/ml) and placebo. The odds ratio 
(OR) for taste detection of BitrexTM and A. vera (75 mg/
ml) was calculated as 14.78 and 5.39, respectively. In ad-
dition, the accuracy score for the corresponding solutions 
was the highest as 84% (104/124) and 81% (101/124), 
respectively. The A. vera (75 mg/ml) held the lowest Brier 
score among all solutions.
The ROC curves for BitrexTM and A. vera threshold 
tests against placebo are given in Fig. 2. Accordingly, the 
ROC curve for A. vera threshold test was similar to that 
of BitrexTM (89.5% vs. 90.3%, respectively). The numbers 
represent the participants could detect the bitter taste of 
BitrexTM and A. vera (75 mg/ml) during TSTs. This sug-
gests that the performance of A. vera threshold solution 
(75 mg/ml) was similar to that of BitrexTM.
The results of A. vera threshold tests against BitrexTM 
are summarized in Table 3. As seen, no significant dif-
ferences were found between the A. vera (concentration 
range of 41.7 to 91.7 mg/ml) and BitrexTM threshold 
tests. Among all solutions, the OR for taste detection of 
A. vera (75 mg/ml) in comparison to BitrexTM was the 
highest (OR=0.37). The significant agreement between 
the BitrexTM and A. vera (75 mg/ml) threshold tests was 
calculated as the highest value (k=0.88).
Figure 3 reveals the overall performance of BitrexTM 
and A. vera threshold tests against a placebo through com-
paring the correspondence AUC curves. Obviously, the 
AUC curves for those solutions overlapped. No significant 
differences were observed between the BitrexTM and A. 
vera threshold tests (p=0.66). Since the ROC curve for the 
Fig. 1. Moldex fit test hood used in the current study.
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95% CI for OR
Accuracy Brier Score AUC
95% CI  for AUC
Lower Upper Lower Upper
Commercial 0.135 2.69** 14.78 3.15 0.18 0.84 0.32 0.9 0.85 0.95
BitrexTM
A. vera 10.7 0.84 2.32 0.92 0.05 0.78 0.14 0.85 0.78 0.91
18.8 −0.09 0.92 0.40 0.14 0.71 0.39 0.76 0.68 0.83
26.2 −0.09 0.92 0.40 0.39 0.72 0.31 0.78 0.71 0.85
41.7 0.98*** 2.65 1.03 0.31 0.78 0.14 0.85 0.79 0.92
58.3 0.98*** 2.65 1.03 0.14 0.78 0.13 0.85 0.79 0.92
75.0 1.68*** 5.39 1.78 0.13 0.81 0.05 0.89 0.84 0.95
91.7 0.98*** 2.65 1.03 0.048 0.78 0.11 0.86 0.8 0.92
*Adjusted for age/gender, **p-value<0.0001, ***p-value<0.05.
MELR: Mixed Effect Logistic Regression; CI: confidence interval; OR: odds ratio; AUC: Area under the ROC Curve.
Fig. 2. Receiver operating characteristic (ROC) curves for threshold tests against placebo: BitrexTM(a), A. vera; 
41.7 and 58.3 mg/ml (b), 75 mg/ml (c), 91.7 mg/ml (d).
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A. vera (75 mg/ml) threshold solution moved to left and 
upside (BitrexTM), it is apparent that its efficacy is similar 
to that of BitrexTM and could be employed as a qualita-
tive fit test agent. Interestingly, the Cost-Benefit Analysis 
(CBA) of the current study indicates that the cost and 
time required to access A. vera solution were remarkably 
less than BitrexTM one (Where cost is $84/100 gr versus 
$2/100 gr, and time between purchase and delivery is 1 
business day versus 14 business days).
Discussion
The aim of this study is to investigate the efficacy of 
A. vera compared to BitrexTM as a qualitative challenge 
agent. The principal points found from this research will 
be discussed below in more detail.
First, the proposed MELR model demonstrated that 
there were no statistically significant differences between 
the BitrexTM and A. vera (41.7, 58.3, 75, and 91.7 mg/ml) 
threshold test results. This means that participants could 
detect the bitter taste using either BitrexTM or A. vera solu-
tion. The minimum concentration of A. vera to develop the 
threshold solution was considered be 41.7 mg/ml. Accord-
ingly, A. vera solution could be made on-site with similar 
efficacy to that of BitrexTM.
Second, the degree of agreement between the results 
of BitrexTM and A. vera (75 mg/ml) threshold tests was 
considered very good (k=0.88) which highlights the high 







95% CI for OR
Kappa (k)
95% CI for Kappa
Lower Upper Lower Upper
A. vera 10.7 −1.85** 0.16 0.03 0.78 0.82 0.71 0.92
18.8 −2.77*** 0.06 0.01 0.29 0.69 0.57 0.82
26.2 −2.77*** 0.06 0.01 0.29 0.69 0.57 0.82
41.7 −1.71 0.18 0.04 0.09 0.82 0.71 0.92
58.3 −1.71 0.18 0.04 0.09 0.85 0.75 0.94
75.0 −1.00 0.37 0.07 2.02 0.88 0.79 0.97
91.7 −1.71 0.18 0.04 0.09 0.85 0.75 0.94
* Adjusted for age/gender, **p-value<0.05, ***p-value<0.0001.
MELR: Mixed Effect Logistic Regression; CI: confidence interval; OR: odds ratio.
Fig. 3. Comparison of area under the ROC curves (AUC) for threshold solutions: BitrexTM and A. vera; 75 mg/ml 
(a), 41.7, 58.3, and 75 mg/ml (b).
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efficacy of A. vera in order to use as a qualitative fit test 
agent. This finding is consistent with the study of Brett G. 
Mitchell et al.11), which states that on-site made solutions 
could be replaced by commercial products for qualitative 
fit testing of respirators. The ability to produce A. vera so-
lution on-site is a critical factor to making a key difference 
in the event of an influenza pandemic or similar respira-
tory diseases. If the testing solution was either not readily 
available or too costly, the facility could incur preventable 
loss of both profit and life.
Another important finding has to do with the fact that 
the majority of the participants tasted both the BitrexTM 
and A. vera (75 mg/ml) solutions. The OR for taste detec-
tion of these mentioned solutions was 14.78 and 5.39 
times the OR for the placebo, respectively, meaning that 
the OR for taste detection of the BitrexTM was almost 
2.70 times the OR for taste detection of A. vera (75 mg/
ml) solution. This means that participants were 2.70 times 
more likely to detect the bitter taste of BitrexTM than that 
of A. vera (75 mg/ml) solution. The AUC for those solu-
tions overlapped, which confirms that A. vera (75 mg/ml) 
solution has similar efficacy to that of BitrexTM.
Noticeably, BitrexTM was detected more often than A. 
vera (75 mg/ml) (96.8% vs. 91.9%). This is consistent with 
some published studies (Mullins, 1995; Roy T. McKay, 
2000) that discussed easier detectability of BitrexTM com-
pared with saccharin12, 36). The mean of the sprays’ number 
to detect the bitter taste of BitrexTM and A. vera (75 mg/
ml) were almost the same (5.32, 6.23, respectively). We 
can also merge those two thoughts as “The CBA obtained 
from the laboratory test confirm that A. vera (75 mg/ml) 
could be utilized as a challenge agent of qualitative fit test, 
which is beneficial”.
The overall cost of A. vera was 42 times (97.6%) lower 
than that of BitrexTM. Additionally, the required time for 
preparation of A. vera fit test solution was lower than that of 
BitrexTM. In fact, on an average, 14 business days required 
for the commercial solution to be delivered. Whereas, the A. 
vera could be available about one business day.
Finally, a number of important limitations need to be con-
sidered. First, the TSTs of the current study were based on 
the subjective reaction to the challenge agents like the other 
qualitative fit test solutions. Second, any variation from the 
fit test protocol would invalidate the test results, including 
the hood size, changes in the concentration of the solutions, 
squeezing the nebulizer bulb, and the number of squeezes.
Conclusion
This study suggests that replacing of A. vera solution 
with a commercial product as a challenge agent in fit test-
ing procedure would be a cost-effective technique; due to 
factors as performance, cost, and availability. It should be 
emphasized that the studied solutions are safe for micro-
bial communications and some physicochemical properties 
of the solutions (taste, color or clearance) were monitored 
over the course of the study and we can safely assure that 
these properties are constant. To do so, it is feasible to uti-
lize the herbal solutions (i.e., A. vera) as challenge agents 
for qualitative fit testing of particulate respirators.
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